This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Using our Arestat™ technology platform, we are developing next generation therapies for our proprietary pipeline and in partnership with leading pharmaceutical and biotech companies
Our Products
Our treatments for people living with chronic disease are designed to advance patient care and improve clinical outcomes
Our Partners
We work with many of the top 20 leading pharmaceutical companies to improve their products, find solutions or create next generation products
Latest News and Events
-
17th December 2020
ARECOR’S PARTNER INHIBRX EXERCISES ITS OPTION TO LICENSE A NEW FORMULATION DEVELOPED BY ARECOR
-
16th December 2020
Arecor Announces Publication Of Phase I Data For AT247 in Diabetes Care
-
14th December 2020
First patient dosed in Phase I clinical trial of Ultra-Concentrated Rapid Acting Insulin candidate, AT278, for diabetes